MAPK inhibitor sensitivity scores predict sensitivity driven by the immune infiltration in pediatric low-grade gliomas.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
27 07 2023
27 07 2023
Historique:
received:
16
12
2022
accepted:
18
07
2023
medline:
31
7
2023
pubmed:
28
7
2023
entrez:
27
7
2023
Statut:
epublish
Résumé
Pediatric low-grade gliomas (pLGG) show heterogeneous responses to MAPK inhibitors (MAPKi) in clinical trials. Thus, more complex stratification biomarkers are needed to identify patients likely to benefit from MAPKi therapy. Here, we identify MAPK-related genes enriched in MAPKi-sensitive cell lines using the GDSC dataset and apply them to calculate class-specific MAPKi sensitivity scores (MSSs) via single-sample gene set enrichment analysis. The MSSs discriminate MAPKi-sensitive and non-sensitive cells in the GDSC dataset and significantly correlate with response to MAPKi in an independent PDX dataset. The MSSs discern gliomas with varying MAPK alterations and are higher in pLGG compared to other pediatric CNS tumors. Heterogenous MSSs within pLGGs with the same MAPK alteration identify proportions of potentially sensitive patients. The MEKi MSS predicts treatment response in a small set of pLGG patients treated with trametinib. High MSSs correlate with a higher immune cell infiltration, with high expression in the microglia compartment in single-cell RNA sequencing data, while low MSSs correlate with low immune infiltration and increased neuronal score. The MSSs represent predictive tools for the stratification of pLGG patients and should be prospectively validated in clinical trials. Our data supports a role for microglia in the response to MAPKi.
Identifiants
pubmed: 37500667
doi: 10.1038/s41467-023-40235-8
pii: 10.1038/s41467-023-40235-8
pmc: PMC10374577
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4533Informations de copyright
© 2023. The Author(s).
Références
Target Oncol. 2017 Feb;12(1):97-109
pubmed: 27975152
J Hematol Oncol. 2021 Jan 5;14(1):1
pubmed: 33402199
Carcinogenesis. 2014 Jul;35(7):1491-9
pubmed: 24445144
Nat Commun. 2013;4:2612
pubmed: 24113773
Oncotarget. 2017 Mar 28;8(13):20825-20833
pubmed: 28212559
Neuro Oncol. 2023 Apr 19;:
pubmed: 37075810
Cancer Cell. 2014 May 12;25(5):697-710
pubmed: 24746704
J Immunother Cancer. 2022 Mar;10(3):
pubmed: 35292516
Cancer Res. 2008 Nov 1;68(21):8673-7
pubmed: 18974108
Cancer Discov. 2021 Nov;11(11):2764-2779
pubmed: 34373263
Signal Transduct Target Ther. 2020 Jul 29;5(1):137
pubmed: 32728057
Sci Rep. 2019 Oct 23;9(1):15222
pubmed: 31645597
J Biotechnol. 2017 Nov 10;261:53-62
pubmed: 28803971
Lancet Oncol. 2019 Jul;20(7):1011-1022
pubmed: 31151904
Acta Neuropathol Commun. 2020 Feb 21;8(1):21
pubmed: 32085805
Oncotarget. 2017 Feb 14;8(7):11460-11479
pubmed: 28002790
Cell. 2020 Dec 23;183(7):1962-1985.e31
pubmed: 33242424
J Cancer. 2019 Oct 17;10(25):6314-6326
pubmed: 31772664
JCO Precis Oncol. 2020 May 20;4:
pubmed: 32923898
Cancer Res. 2010 Mar 15;70(6):2264-73
pubmed: 20215513
Nature. 2006 Jan 19;439(7074):353-7
pubmed: 16273092
Nat Rev Cancer. 2015 Oct;15(10):577-92
pubmed: 26399658
Nature. 2019 Sep;573(7775):532-538
pubmed: 31534219
Gynecol Oncol. 2019 Jul;154(1):95-101
pubmed: 31118140
Nat Genet. 2006 May;38(5):500-1
pubmed: 16642009
Mol Cancer Ther. 2020 Aug;19(8):1736-1750
pubmed: 32451331
Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14903-8
pubmed: 20668238
J Thorac Oncol. 2017 Mar;12(3):556-566
pubmed: 27876675
BMC Genomics. 2021 Apr 15;22(1):272
pubmed: 33858332
Oncogene. 2018 Mar;37(12):1576-1593
pubmed: 29326440
Lancet Oncol. 2020 Jun;21(6):e305-e316
pubmed: 32502457
Cancer Cell. 2017 Jul 10;32(1):42-56.e6
pubmed: 28697342
Cancer Res. 2012 Jul 1;72(13):3228-37
pubmed: 22552284
Nat Med. 2015 Nov;21(11):1318-25
pubmed: 26479923
Endocr Rev. 2019 Dec 1;40(6):1573-1604
pubmed: 31322645
Eur J Cancer. 2023 Feb;180:71-84
pubmed: 36542877
Cell Rep. 2017 Oct 31;21(5):1399-1410
pubmed: 29091775
NPJ Genom Med. 2022 Mar 16;7(1):20
pubmed: 35296678
Clin Cancer Res. 2022 Sep 15;28(18):4056-4069
pubmed: 35792866
Nat Mater. 2019 May;18(5):422-427
pubmed: 30478452
J Natl Cancer Inst. 2007 Jan 17;99(2):147-57
pubmed: 17227998
Neuro Oncol. 2023 Mar 14;25(3):566-579
pubmed: 35882450
Nat Commun. 2019 Aug 19;10(1):3731
pubmed: 31427603
Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):5957-62
pubmed: 23533272
Oncogene. 2022 Jan;41(4):461-475
pubmed: 34759345
Signal Transduct Target Ther. 2020 Mar 20;5(1):22
pubmed: 32296018
Cell Death Dis. 2022 May 25;13(5):496
pubmed: 35614034
Sci Rep. 2021 Oct 27;11(1):21206
pubmed: 34707096
J Allergy Clin Immunol. 2022 Jan;149(1):89-101
pubmed: 33891981
Neuro Oncol. 2021 Oct 1;23(10):1634-1646
pubmed: 34131743
Clin Cancer Res. 2019 Dec 15;25(24):7303-7311
pubmed: 31811016
Front Cell Neurosci. 2018 Aug 06;12:242
pubmed: 30127723
Biochem Biophys Res Commun. 1986 Jan 29;134(2):565-71
pubmed: 3511906
Dev Cell. 2021 Oct 25;56(20):2871-2885.e6
pubmed: 34428430
Clin Cancer Res. 2019 Mar 15;25(6):1851-1866
pubmed: 30530705
Oncologist. 2020 Dec;25(12):e1893-e1899
pubmed: 32776632
Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13086-91
pubmed: 17666531
Sci Rep. 2021 Jan 27;11(1):2369
pubmed: 33504883
J Neurooncol. 2020 Sep;149(3):499-510
pubmed: 33026636
Nucleic Acids Res. 2013 Jan;41(Database issue):D955-61
pubmed: 23180760
J Clin Oncol. 2007 Feb 20;25(6):682-9
pubmed: 17308273
Neuro Oncol. 2023 Apr 6;25(4):735-747
pubmed: 35977048
Cancer Discov. 2019 Mar;9(3):329-341
pubmed: 30770389
Ann Oncol. 2016 Apr;27(4):693-9
pubmed: 26802155
J Clin Oncol. 2022 Jul 10;40(20):2235-2245
pubmed: 35363510
Cell. 2015 Sep 10;162(6):1271-85
pubmed: 26359985
Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4519-24
pubmed: 19251651
J Invest Dermatol. 2008 Aug;128(8):2003-12
pubmed: 18323787
Cancer Cell. 2020 Apr 13;37(4):569-583.e5
pubmed: 32289278
Nature. 2019 Sep;573(7775):539-545
pubmed: 31534222
Brain. 2019 Jan 1;143(1):131-149
pubmed: 31834371
Sci Data. 2018 Apr 17;5:180061
pubmed: 29664468
Oncotarget. 2017 Dec 26;9(19):14828-14848
pubmed: 29599910
Cell Genom. 2023 May 31;3(7):100340
pubmed: 37492101
Nat Commun. 2020 Nov 30;11(1):6129
pubmed: 33257666
Cancer Discov. 2014 Oct;4(10):1214-1229
pubmed: 25256614
Signal Transduct Target Ther. 2022 Jun 24;7(1):198
pubmed: 35750683
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Cancer Res. 2007 Mar 1;67(5):2226-38
pubmed: 17332353
Invest New Drugs. 2018 Dec;36(6):1037-1043
pubmed: 29785570
J Immunol. 2012 Feb 1;188(3):1402-10
pubmed: 22190182
Nat Neurosci. 2016 Jan;19(1):20-7
pubmed: 26713745
Glia. 2011 Aug;59(8):1181-9
pubmed: 21192095
NPJ Precis Oncol. 2018 Mar 7;2(1):7
pubmed: 29872725
Sci Rep. 2020 Jun 24;10(1):10258
pubmed: 32581224
Neuro Oncol. 2011 Feb;13(2):223-34
pubmed: 21177781
Int J Mol Med. 2017 Jun;39(6):1338-1346
pubmed: 28440493
Eur J Cancer. 2017 Aug;81:206-225
pubmed: 28649001
BMC Bioinformatics. 2019 Aug 22;20(1):433
pubmed: 31438843
Nat Rev Cancer. 2017 Nov;17(11):676-691
pubmed: 28984291
Clin Cancer Res. 2015 Apr 1;21(7):1652-64
pubmed: 25617424
Neuro Oncol. 2022 Sep 6;24(Suppl 3):iii1-iii38
pubmed: 36066969
Commun Biol. 2021 Jan 4;4(1):9
pubmed: 33398072
Cell. 2018 Apr 5;173(2):321-337.e10
pubmed: 29625050
J Microsc Ultrastruct. 2019 Apr-Jun;7(2):53-56
pubmed: 31293885
Mol Cancer Ther. 2020 Feb;19(2):525-539
pubmed: 31748345
Leukemia. 2022 Apr;36(4):1088-1101
pubmed: 35082402